<DOC>
	<DOCNO>NCT00748605</DOCNO>
	<brief_summary>1 . To evaluate weight loss effect 1600 mg/day S-2367 administer orally daily morning meal 6-week low calorie diet ( LCD ) 950 kcal/day without S-2367 follow 54 week 800 kcal deficit reduce calorie diet ( RCD ) compare placebo medically stable otherwise healthy obese male female subject 2 . To evaluate safety tolerability 1600 mg/day S-2367 administer orally daily morning meal 6-week LCD without S-2367 follow 54 week RCD compare placebo medically stable otherwise healthy obese male female subject 3 . To evaluate steady-state/trough pharmacokinetics 1600 mg/day S-2367 administer orally daily morning meal 6-week LCD without S-2367 follow 54 week RCD obese male female subject 4 . To evaluate weight loss effect 1600 mg/day S-2367 administer orally daily morning meal initial 6-week LCD compare placebo medically stable otherwise healthy obese male female subject</brief_summary>
	<brief_title>Phase IIb One Year Efficacy Safety Study S-2367 Obese Subjects With Initial 6-Week Low Calorie Diet</brief_title>
	<detailed_description />
	<criteria>Males females 18 65 year age body mass index 30.0 45.0 kg/m2 , inclusive , weight fluctuate 3 % last 3 month Medically stable 3 month prior Visit 1 otherwise good health , clinically significant finding medical history , physical examination , 12lead electrocardiogram ( ECGs ) , vital sign Clinical laboratory evaluation ( include clinical chemistry [ fast least 8 hour ] , complete blood count , urinalysis , include creatine phosphokinase , amylase , lipase , lipid profile , insulin , Homeostatic Model Assessment Insulin Sensitivity Index , hemoglobin A1c , thyroid stimulate hormone , free thyroxine , cortisol , iron , ferritin ) within reference range test laboratory , unless deem clinically significant investigator Males sterile agree use approve method contraception . Some approve method contraception male include surgically sterile ( least 3 month prior Visit 1 ) female sexual partner ; postmenopausal ( least 1 year since last menstrual cycle ) female sexual partner ; female sexual partner us ( least previous 3 month prior Visit 1 study ) oral , implantable , transdermal , injectable oral contraceptive ; use follow doublebarrier method : male condom spermicide Females nonpregnant , nonlactating , either postmenopausal least 1 year since last menstrual period , surgically sterile least 3 month prior Visit 1 , agree use approve method contraception . Some approve method contraception female include sterile ( least 3 month prior Visit 1 ) male sexual partner ; use oral , implantable , transdermal , injectable oral contraceptive ; use one follow doublebarrier method : intrauterine device spermicide , diaphragm spermicide , cervical cap spermicide , female condom spermicide , male condom spermicide male sexual partner Able understand willing sign inform consent form comply study procedure History clinical manifestation significant metabolic , hepatic , immunological ( e.g. , human immunodeficiency virus/ acquire immunodeficiency syndrome ) , renal , hematological , pulmonary , cardiovascular , gastrointestinal ( GI ) , urological , neurological , psychiatric disorder History presence abnormal ECG , investigator 's opinion , clinically significant History evidence psychological disorder , stable control anxiety depression , include limited schizophrenia . Treatment antidepressant anxiolytic drug ( ) permit dose form remain stable least previous 3 month medication precluded/ exclude protocol potential effect body weight expected change remainder clinical protocol History evidence eat disorder compensatory behavior `` purge bulimia nervosa '' `` nonpurging bulimia nervosa '' History obesity endocrine origin History Type 1 Type 2 diabetes mellitus Clinically significant hypertension define blood pressure &gt; 160/90 mm Hg either systolic diastolic value either untreated treated state Clinically significant GI history surgery . NOTE : Appendectomy cholecystectomy allow Gastric bypass surgery , stomach band surgery , surgical procedure ( ) attempt promote/aid weight loss History polycystic ovarian syndrome History fenfluramine dexfenfluramine `` fenphen '' administration abnormal finding echocardiograms time `` fenphen '' discontinuation History participation weight loss program within 3 month prior Visit 1 History body weight loss gain great 3 % within 3 month prior Visit 1 History alcoholism drug addiction/ substance abuse within 1 year prior Visit 1 History tobaccocontaining nicotinecontaining product use within 1 year prior Visit 1 Participation investigational study drug trial receipt investigational study drug occur within 3 month prior Visit 1 Previous use participation study S2367 neuropeptide Y5 agonist antagonist Participation weight loss medication/product study receipt weight loss medication/product occur within 3 month prior Visit 1 Use prescription nonprescription overthecounter ( OTC ) medication/product herbal/phytotherapeutic/plantderived medications/products within 3 month prior Visit 1 intend induce weight loss , appetite suppression , weight control , treat obesity Use chronic medications/products within 3 month prior Visit 1 study know cause weight gain . The list include limited amitriptyline ( Elavil ) , paroxetine ( Paxil ) , setraline ( Zoloft ) , mirtazepine ( Remeron ) Use prescription nonprescription OTC medications/products within 1 month prior Visit 1 , unless deem acceptable investigator . Donation blood blood product 3 month prior Visit 1 entire study Any acute chronic condition , opinion investigator , would limit subject 's ability complete and/ participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Obesity</keyword>
</DOC>